Tissue-Engineered Skin (Apligraf) in the Healing of Patients With Epidermolysis Bullosa Wounds

Abstract

Background: At present, wound treatment of inherited epidermolysis bullosa (EB) is only supportive.Objective: To determine the safety and clinical effects of tissue-engineered skin (Apligraf; Organogenesis Inc, Canton, Mass) in the healing of wounds of patients with different types of EB.Design: An open-label uncontrolled study of 15 patients with EB treated with tissue-engineered skin.Each patient received tissue-engineered skin on up to 2 wounds on each of 3 clinic visits: day 1, week 6, and week 12.They were evaluated 7 ( ± 3) days and 6 weeks after each round of treatment.A quality-of-life survey was administered during week 6.